Pneumopathie interstitielle associée à la sclérodermie systémique : nouveaux développements [New developments in systemic sclerosis-associated interstitial lung disease]

Détails

ID Serval
serval:BIB_F548E305A39A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Pneumopathie interstitielle associée à la sclérodermie systémique : nouveaux développements [New developments in systemic sclerosis-associated interstitial lung disease]
Périodique
Revue medicale suisse
Auteur(s)
Humair G., Daccord C., Beigelman-Aubry C., Lazor R.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
18/11/2020
Peer-reviewed
Oui
Volume
16
Numéro
715
Pages
2218-2223
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
Interstitial lung disease is a frequent complication of systemic sclerosis and has now become the leading cause of death in this disorder. It mainly occurs during the first five years after the diagnosis of systemic sclerosis. Various risk factors are associated with the occurrence of interstitial lung disease, including the presence of anti-topoisomerase I antibodies (Scl-70) and the diffuse cutaneous form of systemic sclerosis. The most common radio-pathological presentation is nonspecific interstitial pneumonia, followed by usual interstitial pneumonia. The classical immunosuppressive treatment of systemic sclerosis-associated interstitial lung disease is evolving, as recent studies suggest a beneficial effect of biological agents such as rituximab and tocilizumab, and antifibrotic drugs such as nintedanib.
Pubmed
Création de la notice
23/11/2020 14:18
Dernière modification de la notice
19/12/2020 7:26
Données d'usage